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Abstract 
Background: Heterogeneity has been noted in the selection and reporting of disease-specific, pediatric outcomes 
in randomized controlled trials (RCTs). The consequence is invalid results or difficulty comparing results across trials. 
The primary objective of this systematic review was to assess primary outcome and outcome measure selection and 
reporting, in pediatric eosinophilic esophagitis (EoE) treatment trials. As secondary objectives, we compared trial 
disease definition to established concensus guidelines, and the efficacy of current EoE treatments.
Methods: We searched MEDLINE, EMBASE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CEN-
TRAL), and CINAHL since 2001. We also searched clinical trial registries (portal.nihr.ac.uk; clinicaltrials.gov; isrctn.com; 
and anzctr.org.au) and references of included studies. We included RCTs of EoE treatment in patients 0–18 years. Two 
authors independently assessed articles.
Results: Eleven studies met inclusion criteria. All identified primary outcomes, however, of 9 unique primary out-
comes, only 2 were used in more than one study. In total, 25 unique primary and secondary outcome measures 
were employed for pediatric EoE treatment trials. Measurement properties and rationale for their selection was rarely 
provided. Uptake of consensus-based diagnostic criteria was 25 % in trials initiated after 2011. Due to the small num-
ber and heterogeneity of studies obtained, no meta-analysis of treatment efficacy could be undertaken. This SR was 
limited to exclusively pediatric RCTs.
Conclusions: The results of this study confirm the need for a standardized set of core outcomes that are universally 
reported in pediatric EoE trials. Consistent disease definition and standardized outcome reporting will facilitate meta-
analyses across similar trials and inform future clinical decision-making.
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Background
In randomized controlled clinical trials (RCTs,) the pri-
mary outcome is “the outcome of greatest importance,” 
[1] and is also the variable that determines calculation 
of the sample size. Outcome measures, in contrast, are 
the tools used to measure the primary outcome, and 
may be scales, questionnaires, scoring systems or other 
instruments [2, 3]. Although RCTs are universally rec-
ognized as the gold standard for determining treatment 
efficacy, the validity of their results depends on the selec-
tion of the most appropriate primary outcomes, valid 
outcome measurement instruments, and full reporting of 
the originally stated primary outcomes [4].
A more standardized approach to the selection of out-
come measures for disease-specific pediatric RCTs has 
been proposed as one strategy to help facilitate knowl-
edge synthesis [5]. Standardized outcome selection and 
reporting, regardless of statistical significance, might also 
minimize outcome reporting bias [6]. Selective outcome 
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reporting is now well accepted as a significant impedi-
ment to knowledge translation and meta-analysis [7]. To 
this end, initiatives such as the Consolidated Standards of 
Reporting Trials (CONSORT) have been established to 
help promote transparent and complete reporting [1, 8].
In order to facilitate outcome measure selection, the 
consensus-based standards for the selection of health 
measurement instruments (COSMIN) group developed 
an international consensus on the terminology and defini-
tions of measurement properties [9]. They identified three 
domains of measurement properties: reliability, validity, 
and responsiveness. Other international initiatives aiming 
to improve selection and reporting of outcome measures 
include the COMET initiative (Core Outcome Measures in 
Effectiveness Trials), which is an initiative to develop a core 
set of outcome measures for each condition [4].
Methods for appropriate selection of outcome meas-
ures in clinical trials have been studied, to some extent, in 
adults, but very few studies have addressed this problem 
in children [3]. The validity of outcome measures chosen 
in pediatric RCTs, as well as the adequacy of their report-
ing, has been called into question [2, 3, 5, 10]. A recent 
systematic review (SR) of pediatric RCTs found that more 
than 10  years after CONSORT guidelines were devel-
oped, 25  % of pediatric RCTs published in high impact 
journals still failed to identify a primary outcome [11]. 
Furthermore, measurement properties of outcome meas-
ures were often not reported. Other systematic reviews 
within specific clinical subspecialities have identified 
similar problems [12–14].
In order to examine the issues surrounding outcome 
measure selection and reporting in pediatric RCTs in 
greater depth, a systematic review within a clinical subspe-
cialty of pediatrics was planned. Eosinophilic esophagitis 
(EoE) is an immune-mediated inflammatory disease of the 
esophagus defined by symptoms of esophageal dysfunction 
and histopathologic findings. This particular condition 
was strategically chosen as it is a relatively new condition, 
where many RCTs on the topic would be expected to have 
been designed well after the development of COSMIN 
and CONSORT guidelines. Furthermore, heterogenous 
disease definition in EoE was identified relatively early 
on, as being an issue in the EoE literature [15]. In 2007, in 
order to address some of these concerns, the First Inter-
national Gastrointestinal Eosinophil Research Symposium 
(FIGERS) published consensus guidelines to help improve 
treatment and diagnosis of EoE (Table  1) [16]. By 2011, 
newer updated guidelines, including a revised “conceptual 
definition” of EoE was developed [17].
The most recent definition states that EoE is a “chronic, 
immune/antigen-mediated esophageal disease character-
ized clinically by symptoms related to esophageal dys-
function and histologically by eosinophil-predominant 
inflammation” [17]. This definition, and its accompany-
ing diagnostic guidelines, emphasizes that both clinical 
features of esophageal dysfunction, and pathologic fea-
tures of the disease must be present. The presence of ≥15 
Eo/HPF in at least one endoscopic esophageal mucosal 
biopsy and/or the presence of other microscopic features 
of eosinophilic inflammation is required for diagnosis. 
As well, in order to exclude children with PPI-responsive 
esophageal eosinophilia, an 8-week trial of PPI prior to 
diagnosis is now also recommended.
The 2011 revisions were a response to certain some-
what arbitrary requirements in the original definition (e.g. 
histologic finding of 15 or more Eo/HPF), which carry 
no proven biologic significance or power to discriminate 
amongst the various esophageal diseases. The require-
ment to rule out GERD (either via failure of PPI treat-
ment or a normal PH impedance study) had not been 
rigorously applied to subsequent studies, nor validated. 
Furthermore, no studies were published since the origi-
nal consensus report that could allow diagnosis based on 
a pathognomonic clinical/histologic feature or biomarker.
Objectives
This SR assessed the heterogeneity of outcome measure 
selection and reporting in exclusively pediatric EoE treat-
ment RCTs. As secondary objectives, this SR assessed the 
heterogeneity of definitions of EoE pre- and post-FIGER 
publication and evidence for current acute treatment 
modalities for EoE in the pediatric population.
Methods
This review was registered on PROSPERO prior to the 
start of the study (CRD42013003798). The search strat-
egy was developed in conjunction with a clinical health 
research librarian.
Data sources
We searched MEDLINE, EMBASE, Cochrane Database 
of Systematic Reviews, Cochrane Central Register of 
Controlled Trials (CENTRAL), and CINAHL, using all 
terms relating to EoE. The search was limited to English-
language studies published between January 2001 and 
December 5, 2014. We also screened the reference lists 
Table 1 FIGERS criteria for EoE [17]
1 Clinical symptoms of esophageal dysfunction (in infants and small 
children, GERD-like symptoms and feeding problems; in older 
children and adults, GERD-like symptoms, especially dysphagia or 
esophageal food impaction)
2 ≥15 eosinophils in at least one high-power field and;
3 Either lack of histological response to 6–8 weeks of treatment with 
high-dose proton-pump inhibitor, OR a normal pH monitoring 
study of the distal esophagus
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of included studies and searched selected websites for 
ongoing/registered trials including https://www.portal.
nihr.ac.uk/Pages/NRRArchive.aspx; http://www.clini-
caltrials.gov/; http://www.isrctn.com/; and http://www.
anzctr.org.au/.
Study selection
Studies were selected if they were: (i) RCTs or con-
trolled trials; (ii) were restricted to pediatric patients 
(0–18  years) with EoE; (iii) investigated any modality 
used to treat EoE (e.g. steroids via any route of admin-
istration; immune modulating treatment, mast cell 
inhibitors, monoclonal antibodies; dietary manipulation; 
esophageal dilatation; novel modalities); and (iv) com-
pared treatment to any control (including, but not lim-
ited to, placebo).
Two reviewers (TR, JC) independently screened the 
abstracts and/or full text of identified articles to deter-
mine which ones met criteria. Disagreement was resolved 
through discussion, including with a senior reviewer 
(DA, SV) as needed.
Data collection and analysis
Full texts of all included studies were obtained. Data from 
included studies were independently extracted by the 
two reviewers. Disagreement was resolved through dis-
cussion, including with a senior reviewer as needed. The 
following information was extracted: journal name, pub-
lication year, design of RCT/CCT, sample size, interven-
tion of interest, number of primary outcomes, outcome 
measures used, and details of outcome measurement 
properties. Flexibility in terminology to express “primary 
outcome” was allowed (e.g. main outcome, primary out-
come, end-point etc.). Primary outcomes were examined 
in detail in order to identify their measurement proper-
ties. Information about safety and harms reporting was 
also extracted.
Assessment of methodological quality of included studies
The two reviewers independently assessed included stud-
ies for risk of bias based on the cochrane risk of bias tool 
(http://www.cochrane-handbook.org). Where possible, 
study authors were contacted for additional information. 
While risk of bias assessment was not necessary to meet 
the primary objective of our review, it was useful when 
interpreting data regarding treatment effect.
Results
A total of 1032 unique references were identified through 
database searches and another 124 from trial registries. 
Screening of titles and abstracts excluded 1126 refer-
ences. Thirty full text articles were obtained and eleven 
met all inclusion criteria (see Fig. 1). Six were published 
studies [18–23] and five were registered trial protocols 
[24–28].
Table 2 provides an overview of the primary outcome 
measures selected and reported in these studies.
Table 3 provides an overview of the secondary outcome 
measures selected and reported in these studies.
Outcome measures
All 11 included studies identified at least one primary 
outcome with 8 identifying a single primary outcome 
(Table  2). The number of primary outcomes per study 
ranged from 1 to 4.
Nine different primary outcome measures were found 
and only two were used in more than one study: esopha-
geal eosinophilia (used in 8/11 studies) and safety (used 
in 2/11 studies). Although many of the studies attempted 
to assess similar types of primary outcomes (e.g. out-
comes that included clinical symptoms), the outcome 
measures they selected varied: e.g. “physician global 
assessment score,” “EoE clinical symptoms score,” “clini-
cal severity score.”
Of the 20 different secondary outcomes (Table 3), only 
8 occurred in more than one study: Esophageal eosino-
philia (n =  3), histologic features (n =  3), proteonomic 
features (n =  3), endoscopic features (n =  2), modified 
endoscopy tool (n =  2), symptom scoring tool (n =  2), 
immune features (n  =  2), and adverse events (n  =  2). 
Just as in the primary outcome measures, similar end-
points were often being assessed but used different 
measurement tools. For example, endoscopic features 
were assessed in at least 4 studies, however outcome 
measures were different and included “endoscopic fea-
tures,” “modified endoscopy tool,” and “severity score 
for endoscopy and histology.” Likewise, symptoms were 
assessed in multiple studies (at least 6) but used a vari-
ety of outcome measures (e.g. “patient symptom report,” 
“clinical response,” “symptom scoring tool,” “predominant 
symptom assessment score,” and “pediatric EoE symptom 
severity module”).
Combining both primary and secondary outcomes 
(Table  4), there were 26 unique outcome measures and 
still only 8 that were used in more than one study: esoph-
ageal eosinophilia (n = 9), safety (n = 4), symptom scor-
ing tool (n = 3), histologic features (n = 3), proteonomic 
features (n  =  3), endoscopic features (n  =  2), endos-
copy scoring tool (n = 2) and immune features (n = 2). 
Nevertheless, several different outcome measures were 
often chosen to assess a similar outcome. For example, 
9 distinct outcome measures were used to assess clini-
cal symptoms, and at least 4 different outcome measures 
were used to assess histologic features.
Of the total of 9 unique primary outcomes, 5 (56  %) 
were scales, scoring systems, instruments, questionnaires 
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or other scoring tools. Of the 25 total primary and sec-
ondary outcome measures, 15/25 (60  %) were scales, 
scoring systems, instruments, questionnaires or other 
scoring tools. Table 5 summarizes the outcome measure-
ment tools described.
The measurement properties for chosen instru-
ments were only reported in 4/15 cases, and all were 
unvalidated. Reliability and responsiveness were never 
reported. Rationale was provided for selection of out-
come measures in 6/15 cases, and included “prior use/
reporting of these instruments,” “review of available lit-
erature,” and “ability of the tool to capture a wide range 
of symptoms specific to pediatric EoE.” References were 
provided for 7/15 of the outcome measurements.
Esophageal eosinophilia
Although esophageal eosinophilia is a requisite compo-
nent of the definition of EoE, not all studies measured 
this as an outcome. Furthermore, outcome measures of 
esophageal eosinophilia varied significantly in their defi-
nitions, methods of measurement, and time period of 
assessment. For example, some studies defined histologic 
remission as ≤1 Eo/HPF, while other defined remission 
as ≤5 Eo/HPF or 0–6 Eo/HPF. Other studies assessed 
percent change in peak Eo counts as evidence of treat-
ment efficacy.
Clinical symptoms
Clinical symptoms are also a requisite feature of the dis-
ease, and were often a component of outcome measure-
ment tools. However, measurement of clinical symptoms 
in these studies also varied significantly. For example, 
some of the studies measured combined patient/parent 
and physician assessments, and others focused on one 
or the other. Various symptom-scoring tools were also 
employed.
Disease definition
Of the 11 trials, 8 were initiated after the publication of 
the FIGERS criteria. Four out of these eight trials (50 %) 
met the original FIGERS criteria in their definition of 
EoE (Table 6). The study by Spergel et al. (and the exten-
sion study by Teva Pharmaceuticals) were considered to 
have met the FIGER criteria for defining EoE, although 
Addional references idenfied 
through other sources
(n = 124)
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Fig. 1 Flow diagram
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they accepted patients who had failed a 4  week trial of 
PPI (rather than the 6–8 week required trial outlined in 
the definition). Of the 4 trials that did not meet FIGER 
criteria, reasons were: no requirement for symptoms (2), 
and no requirement for a negative pH probe or PPI trial 
(2). Excluding the Spergel trial and its extension study 
would mean only 2/6 studies met criteria (33 % uptake).
Four studies were initiated after publication of the 
updated EoE consensus guidelines. Only 1 out of 4 (25 %) 
met the new definition for EoE. Three of the studies did 
not require patients to have failed an 8-week trial of PPI 
(as suggested in the new guidelines), two required a more 
stringent definition of esophageal eosinophilia (>20/HPF) 
than required in the guidelines, and one did not require 
symptoms.
Treatment efficacy
Six studies had results available (Table  7). Four studies 
measured the effect of swallowed steroid [18–20, 23], 
while 2 studies measured the effect of intravenous anti-
IL5 therapy [21, 22].
Of the studies measuring swallowed steroid, two 
assessed swallowed fluticasone, while two assessed swal-
lowed budesonide. The three studies comparing swal-
lowed steroid to placebo found that swallowed steroid 
was effective in improving histologic features [18, 20, 23]. 
One of those studies found that swallowed oral viscous 
budesonide was effective in improving symptoms in addi-
tion to endoscopic features. Schaeffer compared systemic 
and topical steroids and found that both were effective 
in achieving histologic and clinical improvement [19]. 
Although prednisone seemed to lead to a greater histo-
logic effect, there was no difference observed between 
systemic and topical steroids in symptom resolution, 
relapse rate or time to relapse.
Of the two intravenous anti-IL5 trials, both found this 
agent to reduce intraepithelial esophageal eosinophilia. 
Spergel et  al. found that while intraepithelial esopha-
geal eosinophilia improved with treatment, symptom 
improvement was observed in all treatment groups, 
including placebo, and was not associated with changes 
in the esophageal eosinophilia [22].
Of the 11 identified studies, only 6 were published 
manuscripts, with relatively low risk of bias overall (see 
Table  8). Unfortunately intervention and controls were 
not sufficiently homogenous across studies to allow for 
comparisons. Meta-analysis in this case is unlikely to pro-
vide meaningful data, even across 3 or 4 swallowed ster-
oid trials, or 2 anti-IL 5 studies. A meta-analysis for EoE 
treatment efficacy was considered; however, given the 
small number of studies, and heterogeneity in interven-
tion type and outcome measures, this was not feasible.
Discussion
This systematic review is one in a series of systematic 
reviews in the PORTal (primary outcomes reporting in 
trials) initiative, led by Dr. Vohra [11]. In PORTal, RCTs 
are evaluated to assess how well they report informa-
tion about primary outcomes and outcome measurement 
instruments. This systematic review used the PORTal 
approach to examine these issues in pediatric EoE.
This systematic review identified a handful of exclu-
sively pediatric EoE treatment trials. A number of out-
comes were selected and reported in these trials, with 
certain measures, such as esophageal eosinophilia, clini-
cal symptoms, safety, histologic features, and endoscopic 
features, re-occurring frequently, but not universally. The 
rationale for selecting outcome measures, and the meas-
urement properties of the outcome measure tools (when 
used), were most often not reported. Based on the identi-
fied studies, no conclusions regarding treatment efficacy 
could be made.
Clinical implications
Prior SRs of EoE treatment suggest a paucity of high 
quality evidence supporting current treatments for this 
condition, which, at this time include steroids, immune 
modulators, dietary modulation, mast cell stabilizers 
and esophageal dilatation [29, 30]. Indeed, much of the 
pediatric management guidelines for EoE are based on 
expert opinion and lower quality sources of evidence, 
such as retrospective observational studies, case reports, 
and case series [31]. Our current SR of pediatric trials 
confirms the need for additional treatment RCTs on the 
topic.
A recent prior SR examined EoE treatment efficacy 
in RCTs of children and adults up to the year 2010 [29]. 
While this review demonstrated heterogeneity in out-
come measures and disease definition, this was not the 
focus of the review and these issues were not investi-
gated thoroughly. Furthermore, that review combined 
adult and pediatric data, neglecting to account for the 
potentially significant differences in disease presentation, 
response to treatment, and outcomes, between adult and 
pediatric populations.
A 2014 SR of dietary treatment for EoE found that die-
tary interventions are effective in producing histologic 
remission in patients with EoE [30]. However, Arias et al. 
combined pediatric and adult data, and included obser-
vational studies and case series.
This is not the first time the question has been raised 
as to whether pediatric and adult EoE are manifestations 
of a single entity, or two distinct diseases [32, 33]. Nota-
bly, pediatric presentations of EoE have been noted to be 
more heterogeneous, and age-dependent, while in adults 
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or older adolescents, the clinical presentation tends to be 
dominated by dysphagia and food impaction [16, 32, 33].
Controversy regarding the most pertinent end points 
in EoE trials has arisen before [34]. A 2011 editorial by 
Hirano noted that symptoms and histopathology on 
endoscopy (generally tissue eosinophilia) have been the 
most widely used outcomes. The editorial questions, 
however, whether, indeed, eosinophilia is an adequate 
or relevant outcome to measure in EoE trials, and urges 
for the validation of a patient-reported outcome instru-
ment. Our results also find that eosinophilia is the most 
frequently selected outcome in pediatric trials.
The heterogeneity across outcome measures, and even 
within individual outcome measures, is not new in this field. 
Indeed, a 2011 editorial noted that even within commonly 
used outcomes, such as esophageal eosinophilia, there is 
variability in the methodology used to quantitate the eosin-
ophils, as well as in the criteria for defining histopathologic 
change (e.g. reduction in peak eosinophilia versus number 
of eosinophils per high power field) [34].
Since EoE is being conceptualized as a clinicopatho-
logic disease, experts in the field have emphasized the 
need for both symptoms and histology to be consid-
ered in any therapeutic trial [35]. Some researchers have 
already suggested that esophageal eosinophilia alone 
is not a sufficient trial primary end point. Fiorentino 
et  al. suggested using clinical outcome assessment tools 
such as patient reported outcomes, where possible, with 
esophageal eosinophilia as a co-primary end point [36].
Significant strides have already been made within EoE 
research community, in order to address issues of out-
come heterogeneity, and the complexity of disease defi-
nition for a disease where understanding continues to 
emerge. Recent American College of Gastroenterology 
(ACG) guidelines confirm the need for a combination 
of symptom and pathologic improvement as treatment 
end points [37]. The development and validation of a 
novel patient-reported outcome measure of dysphagia in 
patients with EoE is to be lauded [38].
However, it must be pointed out that a major limita-
tion in the selection of appropriate outcome measures in 
pediatric EoE trials is our still evolving understanding of 
the natural history of this disease. Although consensus 
groups have urged investigators to select and report rel-
evant outcomes, there is still no “gold standard” outcome 
measure for this disease. Clinical symptoms and histo-
pathologic findings may both turn out to be important 
for diagnosis and outcomes, as these consensus groups 
have suggested, but the relative importance of each is not 
well defined.
Until more information is available regarding the natu-
ral history and pathophysiology of the disease, we would 
suggest that optimal studies in the field should present 
both clinical and histopathologic data and outcomes. Our 
systematic review demonstrated heterogeneity in out-
come measures and disease definition, and will specifi-
cally guide pediatric EoE researchers who aim to design 
high quality pediatric RCTs in the future.
The uptake of the 2006 FIGERS criteria (50 %) in pedi-
atric trials in our review is disappointing. Nevertheless, 
standardization of disease definition across clinical trials 
is a laudable goal. Another group previously investigated 
whether 2006 consensus guidelines for EoE diagnosis 
impacted diagnostic criteria reporting in the literature 
[39]. They found a significant increase in this reporting 
in articles published after the release of guidelines com-
pared with those published earlier (31 vs 6 %, P < 0.001).
Of the 4 studies in our SR initiated after the new 2011 
guidelines, only 1 adhered to the recommendations. Fail-
ure of 8 weeks of a PPI was not a requirement for 3 of the 
4 studies. These studies may inadvertently be examining 
a more heterogeneous population than expected, includ-
ing patients with PPI-responsive esophageal eosinophilia. 
Not consistently including or standardizing presenting 
symptoms of EoE as part of the disease definition makes 
looking at “clinical symptoms” as an outcome measure 
challenging. In some cases, patients did not have sig-
nificant symptoms at baseline, or their symptoms varied 
Table 8 Risk of bias assessment in studies
+ Low risk of bias
−High risk of bias
? Unclear risk of bias
Konikoff [18] Schaefer [19] Dohil [20] Assa’ad [21] Spergel [22] Gupta [23]
Random sequence generation + + + ? + ?
Allocation concealment + + + + + +
Blinding of participants/personnel + – + + + +
Blinding of outcome assessment + + + + + ?
Incomplete outcome data – + – + + +
Selective outcome reporting ? ? + – ? +
Pharmaceutical sponsorship + + + – – –
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dramatically at baseline within and between studies. This 
limits generalizability and comparability of results across 
studies, since studies included patients with varying 
degrees of disease severity. Not adequately defining 
symptoms at the start of the study might also negatively 
impact on ability to detect change over time.
Similar to the Cochrane review conducted by in 2010, 
in our SR, no meta-analysis could be conducted due to the 
limited number of heterogeneous trials identified [29].
Limitations
The relatively low yield of studies in this systematic 
review may be related, in part, to the fact that only tri-
als with exclusively pediatric participants were sought. 
By limiting included studies to those only of children, 
we optimized the likelihood of age-appropriate outcome 
measurement instruments being identified. If a study had 
a mixed adult and pediatric population, it is more likely 
that outcome measures used may be valid and reliable in 
one population but not in both (this would potentially 
disadvantage these studies in our assessment). In addi-
tion, there are data to suggest that symptoms, implica-
tions, and prognosis of EoE vary between children and 
adults [32, 33].
Research implications
Primary and secondary outcome measures selected for 
the study of EoE varied considerably across treatment 
trials. No single outcome measure was selected and 
reported in all trials, which impedes knowledge synthe-
sis. Furthermore, even for outcome measures frequently 
used (e.g. esophageal eosinophilia, clinical symptoms), 
standardized methods regarding how and when to assess 
them were lacking.
In the case of a relatively new and unstudied disease 
like EoE, validated measurement tools are lacking, which 
might partly explain the lack of validated measurement 
instruments being used in the present studies. Effort 
should be focused on validating measurement tools for 
use in the pediatric EoE population for future studies. 
Rationale for selection of outcome measures and appro-
priate references were rarely provided in these studies.
There is growing data showing that attention to stand-
ards for reporting in trials, as in the CONSORT initiative, 
leads to higher quality RCT reporting [8]. EoE is a rela-
tively new condition and will benefit from research to eval-
uate which therapies are most effective. Future research 
would benefit from consistent and standardized defini-
tions of disease occurrence and resolution, and from the 
development of a core outcome set so that investigators 
can agree on what outcomes to measure, when, and how.
Conclusions
The results of this systematic review confirm the need 
for a core set of standardized pediatric outcome meas-
ures that are valid and reliable for future EoE trials. A 
standardized and rigorous approach to outcome measure 
selection, such as the COSMIN criteria would be appro-
priate. Adherence to standardized disease definitions will 
enhance future knowledge synthesis. Identifying and pro-
moting resolution of heterogeneity in the definition of 
EoE and its resolution, as well as addressing the issue of 
heterogeneity in EoE RCT outcome measures, is critical 
to meaningful knowledge synthesis.
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